Hemostasis in liver disease: Implications of new concepts for perioperative management

Transfusion Medicine Reviews

Volumn 28, Issue 3, 2014, Pages 107-113

  Weeder, Pepijn D ^a   Porte, Robert J ^a   Lisman, Ton ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Blood coagulation disorders blood; Blood coagulation disorders etiology; Blood coagulation disorders therapy; Evidence based medicine; Hemostasis physiology; Homeostasis physiology; Humans; Liver diseases blood; Liver diseases complications; Liver diseases therapy

Indexed keywords

ACUTE LIVER FAILURE; ANTICOAGULANT THERAPY; BLEEDING DISORDER; BLEEDING TENDENCY; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; CENTRAL VENOUS PRESSURE; CHEMOPROPHYLAXIS; DEEP VEIN THROMBOSIS; ESOPHAGUS VARICES; HEMODYNAMIC PARAMETERS; HEMOSTASIS; HUMAN; INVASIVE PROCEDURE; KIDNEY FUNCTION; KIDNEY INFECTION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; PARTIAL THROMBOPLASTIN TIME; PATIENT RISK; PERIOPERATIVE PERIOD; PORTAL VEIN BLOOD PRESSURE; PRACTICE GUIDELINE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SPLANCHNIC BLOOD FLOW; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOSIS PREVENTION; WATCHFUL WAITING; BLEEDING; BLOOD; BLOOD CLOTTING DISORDER; COMPLICATION; HEMODYNAMICS; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; THROMBOSIS;

THROMBIN;

BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; HEMODYNAMICS; HEMORRHAGE; HEMOSTASIS; HUMANS; KIDNEY; LIVER DISEASES; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PROTHROMBIN TIME; RISK FACTORS; THROMBIN; THROMBOSIS;

EID: 84903479118     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2014.03.002     Document Type: Review

References (115)

1. Lisman T., Leebeek F.W.G., de Groot P. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002, 37:280-287.
2. Massicotte L., Denault A., Beaulieu D., Thibeault L., Hevesi Z., Nozza A., et al. Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. Transplantation 2012, 93:1276-1281.
3. Dzik W. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004, 3:324-330.
4. Dzik W., Rao A. Why do physicians request fresh frozen plasma?. Transfusion 2004, 44:1393-1394.
5. Lisman T., Leebeek F.W.G. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007, 24:250-258.
6. Caldwell S.H., Hoffman M., Lisman T., Macik B.G., Northup P.G., Reddy K.R., et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006, 44:1039-1046.
7. Ben Ari Z., Osman E., Hutton R.A., Burroughs A.K. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?. Am J Gastroenterol 1999, 94:2977-2982.
8. Lisman T., Bongers T., Adelmeijer J., Janssen H.L.A., de Maat M.P.M., de Groot P., et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006, 44:53-61.
9. Hollestelle M.J., Poyck P.P.C., Hollestelle J.M., Marsman H.A., van Maurik J.A., van Gulik T.M. Extra-hepatic factor VIII expression in porcine fulminant hepatic failure. J Thromb Haemost 2005, 3:2274-2280.
10. Hollestelle M., Geertzen H., Straatsburg I., van Gulik T., van Mourik J. Factor VIII expression in liver disease. J Thromb Haemost 2004, 91:267-275.
11. Cahill P.A., Redmond E.M., Sitzmann J.V. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001, 89:273-293.
12. Aster R.H. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966, 45:645-657.
13. Lisman T., Bakhtiari K., Pereboom I.T.A., Hendriks H.G.D., Meijers J.C.M., Porte R. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010, 52:355-361.
14. Lisman T., Leebeek F.W.G., Mosnier L.O., Bouma B.N., Meijers J.C.M., Janssen H.L.A., et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001, 121:131-139.
15. Rijken D.C., Kock E.L., Guimarães A.H.C., Talens S., Murad S.D., Janssen H.L.A., et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012, 10:2116-2122.
16. Lisman T., Bakhtiari K., Adelmeijer J., Meijers J.C.M., Porte R.J., Stravitz R.T. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012, 10:1312-1319.
17. Pihusch R., Rank A., Göhring P., Pihusch M., Hiller E., Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002, 37:548-555.
18. Ben Ari Z., Panagou M., Patch D., Bates S., Osman E., Pasi J., et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997, 26:554-559.
19. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
20. Younossi Z., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011, 9:524-530. [e1].
21. Lisman T., Caldwell S., Burroughs A., Northup P., Senzolo M., Stravitz R.T., et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010, 53:362-371.
22. Kargili A., Cipil H., Karakurt F., Kasapoglu B., Koca C., Aydin M., et al. Hemostatic alterations in fatty liver disease. Blood Coagul Fibrinolysis 2010, 21:325-327.
23. Munoz S., Stravitz R.T., Gabriel D. Coagulopathy of acute liver failure. Clin Liver Dis 2009, 13:95-107.
24. Munoz S., Rajender Reddy K., Lee W. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008, 9:103-107.
25. Northup P., McMahon M., Ruhl A.P., Altschuler S., Volk Bednarz A., Caldwell S., et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006, 101:1524-1528.
26. Caldwell S., Shah N. The prothrombin time-derived international normalized ratio: great for warfarin, fair for prognosis and bad for liver-bleeding risk. Liver Int 2008, 28:1325-1327.
27. Lisman T., Porte R. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010, 116:878-885.
28. Coêlho G.R., Feitosa Neto B.A., de G Teixeira C.C., Marinho D.S., Rangel M.L.M., Garcia J.H.P. Single-center transfusion rate for 555 consecutive liver transplantations: impact of two eras. Transplant Proc 2013, 45:3305-3309.
29. Segal J., Dzik W. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005, 45:1413-1425.
30. Tripodi A., Mannucci P. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007, 46:727-733.
31. Massicotte L., Beaulieu D., Roy J., Marleau D., Vandenbroucke F., Dagenais M., et al. MELD score and blood product requirements during liver transplantation: no link. Transplantation 2009, 87:1689-1694.
32. Massicotte L., Beaulieu D., Thibeault L., Roy J., Marleau D., Lapointe R., et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation 2008, 85:956-962.
33. Tripodi A., Salerno F., Chantarangkul V., Clerici M., Cazzaniga M., Primignani M., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005, 41:553-558.
34. Stravitz R.T., Lisman T., Luketic V., Sterling R., Puri P., Fuchs M., et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012, 56:129-136.
35. Stravitz R.T., Kramer A., Davern T., Shaikh A.O.S., Caldwell S., Mehta R., et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007, 35:2498-2508.
36. Boks A.L., Brommer E.J., Schalm S.W., Van Vliet H.H. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986, 6:79-86.
37. Mallett S.V., Chowdary P., Burroughs A.K. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int 2013, 33:961-974.
38. Stravitz R.T. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol 2012, 8:513-520.
39. Saner F.H., Gieseler R.K., Akiz H., Canbay A., Görlinger K. Delicate balance of bleeding and thrombosis in end-stage liver disease and liver transplantation. Digestion 2013, 88:135-144.
40. Afshari A., Wikkelsø A., Brok J., Møller A.M., Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev 2011, CD007871.
41. Krzanicki D., Sugavanam A., Mallett S. Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography. Liver Transpl 2013, 19:852-861.
42. Sharara A.I., Rockey D.C. Gastroesophageal variceal hemorrhage. N Engl J Med 2001, 345:669-681.
43. Garcia Tsao G., Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010, 362:823-832.
44. Smyrniotis V., Kostopanagiotou G., Theodoraki K., Tsantoulas D., Contis J. The role of central venous pressure and type of vascular control in blood loss during major liver resections. Am J Surg 2004, 187:398-402.
45. Jones R.M., Moulton C.E., Hardy K.J. Central venous pressure and its effect on blood loss during liver resection. Br J Surg 1998, 85:1058-1060.
46. Feng Z., Xu X., Zhu S., Bein B., Zheng S. Effects of low central venous pressure during preanhepatic phase on blood loss and liver and renal function in liver transplantation. World J Surg 2010, 34:1864-1873.
47. Massicotte L., Lenis S., Thibeault L., Sassine M., Seal R., Roy A. Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. Liver Transpl 2006, 12:117-123.
48. Vaquero J., Fontana R., Larson A., Bass N.M.T., Davern T., Shakil A.O., et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005, 11:1581-1589.
49. Lai C.H., Cheng P.Y., Chen Y.Y. Liver cirrhosis and risk of intracerebral hemorrhage: a 9-year follow-up study. Stroke 2011, 42:2615-2617.
50. Jalal D., Chonchol M., Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost 2010, 36:34-40.
51. Pavord S., Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev 2011, 25:271-278.
52. Goulis J., Armonis A., Patch D., Sabin C., Greenslade L., Burroughs A.K. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998, 27:1207-1212.
53. Vivas S., Rodriguez M., Palacio M.A., Linares A., Alonso J.L., Rodrigo L. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci 2001, 46:2752-2757.
54. Borzio M., Salerno F., Piantoni L., Cazzaniga M., Angeli P., Bissoli F., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001, 33:41-48.
55. de Boer M., Molenaar I.Q., Hendriks H.G.D., Slooff M.J.H., Porte R. Minimizing blood loss in liver transplantation: progress through research and evolution of techniques. Dig Surg 2005, 22:265-275.
56. Tripodi A., Anstee Q.M., Sogaard K.K., Primignani M., Valla D.C. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011, 9:1713-1723.
57. García-Fuster M.J., Abdilla N., Fabiá M.J., Fernández C., Oliver V., Forner M.J. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig 2008, 100:259-262.
58. Huard G., Bilodeau M. Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: a systematic review. Int J Hepatol 2012, 2012:672986-672992.
59. Hoekstra J., Janssen H.L.A. Vascular liver disorders (II): portal vein thrombosis. Neth J Med 2009, 67:46-53.
60. Tsochatzis E.A., Senzolo M., Germani G., Gatt A., Burroughs A.K. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010, 31:366-374.
61. Belli L.M.D., Sansalone C.V.M.D., Aseni P.M.D., Romani F.M.D., Rondinara G.M.D. Portal thrombosis in cirrhotics: a retrospective analysis. Ann Surg 1986, 203:286-291.
62. Ogren M., Bergqvist D., Björck M., Acosta S., Eriksson H., Sternby N.H. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006, 12:2115-2119.
63. Amitrano L., Brancaccio V., Guardascione M.A., Margaglione M., Iannaccone L., D'Andrea G., et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000, 31:345-348.
64. Amitrano L., Guardascione M., Ames P.R.J., Margaglione M., Iannaccone L., Brancaccio V., et al. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. J Thromb Haemost 2006, 95:221-223.
65. Bechmann L., Sichau M., Wichert M., Gerken G., Kröger K., Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011, 31:75-82.
66. Aldawood A., Arabi Y., Aljumah A., Alsaadi A., Rishu A., Aldorzi H., et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 2011, 9:1-6.
67. Villa E., Camma C., Marietta M., Luongo M., Critelli R., Colopi S., et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012, 143:1253-1260. [e1].
68. Fujita K., Nozaki Y., Wada K., Yoneda M., Endo H., Takahashi H., et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008, 57:1583-1591.
69. Ganey P., Luyendyk J., Newport S., Eagle T., Maddox J., Mackman N., et al. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology 2007, 46:1177-1186.
70. Anstee Q.M., Goldin R.D., Wright M., Martinelli A., Cox R., Thursz M.R. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008, 6:1336-1343.
71. Senzolo M., M Sartori T., Rossetto V., Burra P., Cillo U., Boccagni P., et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012, 32:919-927.
72. Amitrano L., Guardascione M., Menchise A., Martino R., Scaglione M., Giovine S., et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010, 44:448-451.
73. Vamvakas E., Blajchman M. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009, 113:3406-3417.
74. Pereboom I.T.A., de Boer M., Haagsma E., Hendriks H.G.D., Lisman T., Porte R. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. Anesth Analg 2009, 108:1083-1091.
75. Massicotte L., Sassine M., Lenis S., Seal R., Roy A. Survival rate changes with transfusion of blood products during liver transplantation. Can J Anaesth 2005, 52:148-155.
76. Cacciarelli T.V., Keeffe E.B., Moore D.H., Burns W., Busque S., Concepcion W., et al. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. Arch Surg 1999, 134:25-29.
77. de Boer M., Christensen M., Asmussen M., van der Hilst C.S., Hendriks H.G.D., Slooff M.J.H., et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008, 106:32-44.
78. Villanueva C., Colomo A., Bosch A., Concepcion M., Hernandez-Gea V., Aracil C., et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013, 368:11-21.
79. Benson A., Austin G., Berg M., McFann K., Thomas S., Ramirez G., et al. Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med 2010, 36:1710-1717.
80. Toy P., Gajic O., Bacchetti P., Looney M., Gropper M., Hubmayr R., et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012, 119:1757-1767.
81. Benson A., Burton J., Austin G., Biggins S., Zimmerman M., Kam I., et al. Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl 2011, 17:149-158.
82. Alter H., Klein H. The hazards of blood transfusion in historical perspective. Blood 2008, 112:2617-2626.
83. Stanworth S.J., Hyde C.J., Murphy M.F. Evidence for indications of fresh frozen plasma. Transfus Clin Biol 2007, 14:551-556.
84. Tinmouth A. Evidence for a rationale use of frozen plasma for the treatment and prevention of bleeding. Transf Apheres Sci 2012, 46:293-298.
85. Afdhal N., Giannini E., Tayyab G., Mohsin A., Lee J., Andriulli A., et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012, 367:716-724.
86. Lisman T., Porte R. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012, 367:2055-2056.
87. Jabbour N., Gagandeep S., Shah H., Mateo R., Stapfer M., Genyk Y., et al. Impact of a transfusion-free program on non-Jehovah's witness patients undergoing liver transplantation. Arch Surg 2006, 141:913-917.
88. Ramos H.C., Todo S., Kang Y., Felekouras E., Doyle H.R., Starzl T.E. Liver transplantation without the use of blood products. Arch Surg 1994, 129:528-532.
89. Rockey D., Caldwell S., Goodman Z., Nelson R., Smith A. Liver biopsy. Hepatology 2009, 49:1017-1044.
90. Patel I., Davidson J., Nikolic B., Salazar G., Schwartzberg M., Walker T.G., et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2012, 23:727-736.
91. Hendriks G.D., Lisman T., Porte R.J. Coagulation and blood transfusion management. Medical care of the liver transplant patient 2012, 276-285. Blackwell Publishing, New Jersey. 4th ed. P. Clavien, J. Trotter (Eds.).
92. Massicotte L., Perrault M., Denault A., Klinck J., Beaulieu D., Roy J., et al. Effects of phlebotomy and phenylephrine infusion on portal venous pressure and systemic hemodynamics during liver transplantation. Transplantation 2010, 89:920-927.
93. Hashimoto T., Kokudo N., Orii R., Seyama Y., Sano K., Imamura H., et al. Intraoperative blood salvage during liver resection: a randomized controlled trial. Ann Surg 2007, 245:686-691.
94. Schroeder R., Collins B., Tuttle Newhall E., Robertson K., Plotkin J., Johnson L., et al. Intraoperative fluid management during orthotopic liver transplantation. J Cardiothorac Vasc Anesth 2004, 18:438-441.
95. Noris M., Remuzzi G. Uremic bleeding: closing the circle after 30years of controversies?. Blood 1999, 94:2569-2574.
96. Lisman T., Caldwell S.H., Porte R.J. Anemia as a potential contributor to bleeding in patients with liver disease-neglected but not forgotten. J Hepatol 2011, 54:594-595.
97. Sihler K.C., Napolitano L.M. Complications of massive transfusion. Chest 2010, 137:209-220.
98. Ramaker A.J., Meyer P., van der Meer J., Struys M.M., Lisman T., van Oeveren W., et al. Effects of acidosis, alkalosis, hyperthermia and hypothermia on haemostasis: results of point-of-care testing with the thromboelastography analyser. Blood Coagul Fibrinolysis 2009, 20:436-439.
99. Xia V.W., Steadman R.H. Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transpl 2005, 11:10-18.
100. Blauhut B. Indications for prothrombin complex concentrates in massive transfusions. Thromb Res 1999, 95:S63-S69.
101. Johansson P.I., Ostrowski S.R., Secher N.H. Management of major blood loss: an update. Acta Anaesthesiol Scand 2010, 54:1039-1049.
102. Samama C.M. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol 2008, 25:784-789.
103. Arshad F., Ickx B., van Beem R.T., Polak W., Grüne F., Nevens F., et al. Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. BMC Surg 2013, 13:22-33.
104. Findlay J.Y., Rettke S.R., Ereth M.H., Plevak D.J., Krom R.A., Kufner R.P. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transpl 2001, 7:802-807.
105. Ramsay M.A. Con: antifibrinolytics are not safe and effective in patients undergoing liver transplantation. J Cardiothorac Vasc Anesth 2006, 20:891-893.
106. Francoz C., Belghiti J., Vilgrain V., Sommacale D., Paradis V., Condat B., et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005, 54:691-697.
107. Potze W., Arshad F., Adelmeijer J., Blokzijl H., van den Berg A.P., Porte R.J., et al. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol 2013, 163:666-673.
108. Lisman T., Porte R. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int 2011, 31:1063.
109. Bechmann L., Wichert M., Kröger K., Hilgard P. Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients. Liver Int 2011, 31:1064.
110. Senzolo M., Rodriguez Castro K.I., Rossetto V., Radu C., Gavasso S., Carraro P., et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012, 10:1823-1829.
111. Lisman T., Porte R. Pitfalls in assessing platelet activation status in patients with liver disease. Liver Int 2012, 32:1027.
112. Levi M., Hovingh G.K., Cannegieter S., Vermeulen M., Büller H., Rosendaal F. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008, 111:4471-4476.
113. Delgado M.G., Seijo S., Yepes I., Achécar L., Catalina M.V., García-Criado A., et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012, 10:776-783.
114. Ozier Y., Pessione F., Samain E., Courtois F. Institutional variability in transfusion practice for liver transplantation. Anesth Analg 2003, 97:671-679.
115. Massicotte L., Sassine M., Lenis S., Roy A. Transfusion predictors in liver transplant. Anesth Analg 2004, 98:1245-1251.